On November 27, 2019 NantKwest, Inc. (Nasdaq: NK), a next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and other diseases, reported that on Monday, December 2, 2019, it will host a key opinion leader (KOL) meeting in New York City on the current treatment landscapes and unmet medical needs of patients with Merkel cell carcinoma, triple-negative breast cancer, solid tumors and the state-of-the-art treatment in the induction of Immunogenic Cell Death (Press release, NantKwest, NOV 27, 2019, https://ir.nantkwest.com/news-releases/news-release-details/nantkwest-hosting-key-opinion-leader-meeting-novel?field_nir_news_date_value[min]=2019 [SID1234551760]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This event will feature presentations from KOLs George Ansstas, MD, Washington University of Medicine in St. Louis, Chaitali Nangia, MD, Chan Soon-Shiong Institute for Medicine, and Clint Allen, MD, Johns Hopkins Kimmel Cancer Center, as well as Dr. Patrick Soon-Shiong, Chief Executive Officer and Chairman of NantKwest.
NantKwest’s management team will also provide pipeline updates on their haNK and PD-L1.t-haNK programs utilizing the Company’s Activated Natural Killer (aNK) cell platform to target these diseases. This platform harnesses the power of the innate immune system and is uniquely positioned to provide broadly available, off-the-shelf cell therapies capable of being administered in the outpatient setting.
Clint Allen, MD is an Associate Professor of Otolaryngology-Head and Neck Surgery at the Johns Hopkins School of Medicine, Principal Investigator of the Translational Tumor Immunology Program, National Institute on Deafness and Other Communication Disorders, NIH. His research focuses on understanding how the immune system responds to squamous cell carcinoma of the head and neck, and how this can be enhanced therapeutically. He leads a large pre-clinical and clinical laboratory program focused on translational pre-clinical studies in syngeneic models of squamous cell carcinoma and the assessment of clinical trial specimens. He is the director of the inpatient Otolaryngology consultation service at the NIH Clinical Center and maintains a surgical practice for the Johns Hopkins School of Medicine based out of Suburban Hospital in Bethesda, MD.
George Ansstas, MD is an Assistant Professor of Medicine, Section of Medical Oncology, Division of Oncology at Washington University School of Medicine. Dr. Ansstas’s clinical expertise includes brain tumors, neuro-oncology, skin cancer, and melanoma. He received his medical degree from University of Tishreen, Latakia, Syria in 2001. Dr. Ansstas completed a fellowship in hematology and oncology at Washington University, St. Louis.
Chaitali Nangia, MD is an Hematologist/Oncologist based in Costa Mesa, California and is affiliated with Hoag Hospital System. She received her medical degree from Lady Hardinge Medical College in New Delhi, India and completed her residency in Internal Medicine at Resurrection Westlake Medical Center in Illinois. She then completed her Fellowship in Hematology/Oncology at the Henry Ford Hospital in Michigan. She worked as an Associate Professor at University of California-Irvine and as an Associate Program Director at University of California-Irvine Hematology/Oncology Fellowship Program prior to her current role. She acted as the principal investigator for several clinical trials and has been an author of several publications.
This event is intended for institutional investors, sell-side analysts, and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited. Members of the media and the public are invited to participate via the live webcast, which can be accessed through our company website at https://nantkwest.com/nantkwest-key-opinion-leader-event/. The event is expected to start at noon EST on Monday, December 2, 2019.